(Q43660046)

25 November 2017

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure (English)

1 reference

25 November 2017

M Sherwood

1

1 reference

PubMed ID

11434939

25 November 2017

J Brandt

series ordinal

2

1 reference

PubMed ID

11434939

25 November 2017

Bimatoprost Study Groups 1 and 2

series ordinal

3

1 reference

25 November 2017

1 May 2001

1 reference

25 November 2017

Survey of Ophthalmology

1 reference

25 November 2017

45 Suppl 4

1 reference

25 November 2017

S361-8

1 reference

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

A useful testing strategy in phase III trials: combined test of superiority and test of equivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Target pressure--glaucomatologists' holey grail.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900219-3

7 January 2021

10.1016/S0039-6257(01)00219-3

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11434939